<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423695</url>
  </required_header>
  <id_info>
    <org_study_id>WISP_RO78</org_study_id>
    <nct_id>NCT01423695</nct_id>
  </id_info>
  <brief_title>Weekly Paclitaxel and Trastuzumab in Metastatic Breast Cancer</brief_title>
  <official_title>Weekly Application of Trastuzumab and Paclitaxel in the Treatment of HER2-overexpressing Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>WiSP Wissenschaftlicher Service Pharma GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>WiSP Wissenschaftlicher Service Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 3 weekly combination of trastuzumab and paclitaxel has been approved for the treatment of
      advanced breast cancer based on a large pivotal study. However, mono and combination
      chemotherapy trials suggest that weekly paclitaxel has a better therapeutic index, especially
      in the palliative setting. The present trial examines the efficacy and safety of weekly
      paclitaxel over a limited duration combined with continued trastuzumab in HER2+ patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Patient follow-up on average for 15 months and up to a maximum of 51 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel/trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single experimental arm in a phase II trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel plus trastuzumab</intervention_name>
    <description>Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)</description>
    <arm_group_label>paclitaxel/trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed metastatic breast cancer overexpressing HER2

          -  pretreatment with anthracycline in either the adjuvant or palliative setting.

          -  HER2 positivity was defined as 2+ or 3+ overexpression using the DAKO HercepTest,
             confirmed by fluorescence in-situ hybridization (FISH) if 2+.

          -  informed consent

        Exclusion Criteria:

          -  more than 1 chemotherapy for advanced disease

          -  taxane or trastuzumab pretreatment

          -  brain metastases

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt;1

          -  pregnancy or lactation, childbearing potential without reliable contraception

          -  clinically significant cardiac disease,

          -  neutrophils &lt;1500/µl, platelets &lt;75,000/µl

          -  total bilirubin and creatinine &gt;1.5 × the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias John, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Practice, Glauchau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Matthias John</name>
      <address>
        <city>Glauchau</city>
        <state>Sachsen</state>
        <zip>D-08371</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>August 25, 2011</last_update_submitted>
  <last_update_submitted_qc>August 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

